Previous close | 535.48 |
Open | 534.10 |
Bid | 536.88 x 1100 |
Ask | 543.00 x 800 |
Day's range | 534.10 - 546.72 |
52-week range | 328.13 - 664.64 |
Volume | 595,502 |
Avg. volume | 924,711 |
Market cap | 57.384B |
Beta (5Y monthly) | 0.30 |
PE ratio (TTM) | 19.71 |
EPS (TTM) | 27.29 |
Earnings date | 05 Feb 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 660.56 |
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.